Yahoo's most recent trend suggests a bullish bias. One trading opportunity on Yahoo is a Bull Put Spread using a strike $36.00 short put and a strike $31.00 long put offers a potential 7.53% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $36.00 by expiration. The full premium credit of $0.35 would be kept by the premium seller. The risk of $4.65 would be incurred if the stock dropped below the $31.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Yahoo is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Yahoo is bullish.
The RSI indicator is at 77.12 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Yahoo
Cramer: Multiple messages from OpenTable deal
Fri, 13 Jun 2014 22:19:47 GMT
CNBC – On Friday, Priceline inked a deal to buy OpenTable for $103 and Cramer says developments are chock full of subtle messages.
Yahoo Shares Power Up As Alibaba Enters U.S. E-Commerce Markets
Fri, 13 Jun 2014 15:32:07 GMT
Fmr. Yahoo COO: Mayer done all right things
Fri, 13 Jun 2014 15:21:00 GMT
CNBC – Jeff Mallett, Yahoo former president and COO, weighs in on the Alibaba IPO and discusses Marissa Mayer's performance as CEO.
Why Allergan's Shareholders Should Be Wary About Valeant's (and Ackman's) Takeover Bid
Thu, 12 Jun 2014 19:10:00 GMT
Forbes – This article is by Mark Rogers, the founder and chief executive of BoardProspects.com. The battle between activist investor Bill Ackman and Allergan's chief executive and board over Valeant Pharmaceuticals' bid to take over Allergan, the maker of Botox, has been generating a lot of news lately. But it’s what doesn’t get much press—what […]
Why The O'Bannon v. NCAA Trial Matters To The Fantasy Sports Industry
Thu, 12 Jun 2014 13:05:00 GMT
Forbes – This week's trial in O'Bannon v. NCAA may affect more than just the college sports industry. It could also affect those who operate fantasy sports businesses. Currently, there is some uncertainty about whether fantasy sports contests may use college athletes' names and statistics in their games without a license. Although the U.S. Court of Appeals for […]
Related Posts
Also on Market Tamer…
Follow Us on Facebook